Korsana Biosciences emerged from stealth with $175 million in venture capital to advance KRSA‑028, an antibody designed to clear amyloid using a BBB shuttle strategy. The financing — led by Wellington, J.P. Morgan Life Sciences Private Capital and Sanofi Ventures — will fund first‑in‑human studies planned for early 2027 and initial proof‑of‑concept plaque reduction readouts later that year. Korsana positions KRSA‑028 to compete in the crowded anti‑amyloid field by emphasizing shuttle-enabled brain penetration and hopes to deliver improved plaque clearance with a differentiated safety profile. Investors characterized the round as a bet on improved delivery modalities and accelerated clinical timelines. The raise underscores ongoing investor appetite for Alzheimer’s biologics despite prior regulatory setbacks and the presence of two approved disease‑modifying antibodies on the market.